Alembic Pharmaceuticals Limited (NSE:APLLTD)

Alembic Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	1,964	834.8	1,202	754.8	610.9
Cash & Short-Term Investments	1,964	834.8	1,202	754.8	610.9
Cash Growth	135.23%	-30.55%	59.26%	23.55%	-78.57%
Accounts Receivable	14,663	13,998	10,248	10,464	8,071
Other Receivables	106.8	110.1	477.5	827.1	250.8
Receivables	14,770	14,108	10,726	11,291	8,322
Inventory	25,106	22,881	16,435	14,753	16,097
Prepaid Expenses	807.6	691.8	500.5	553.2	370.7
Other Current Assets	3,078	2,362	1,922	1,748	3,207
Total Current Assets	45,726	40,878	30,786	29,100	28,608
Property, Plant & Equipment	34,773	33,608	30,711	29,997	39,473
Long-Term Investments	1,409	1,272	930.2	963.3	1,184
Other Intangible Assets	2,868	-	-	-	1,548
Long-Term Deferred Tax Assets	2,696	1,660	1,696	1,230	58.8
Other Long-Term Assets	154.4	311.4	332.9	537.4	348.8
Total Assets	87,626	77,729	64,456	61,828	71,220

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	8,351	8,799	7,356	6,798	7,064
Accrued Expenses	1,997	1,828	1,582	1,418	1,850
Short-Term Debt	12,389	11,956	4,305	6,359	4,300
Current Portion of Long-Term Debt	-	-	-	-	2,000
Current Portion of Leases	243.3	151.6	198.3	169.2	149.8
Current Income Taxes Payable	349.8	189.1	-	-	-
Current Unearned Revenue	112.5	115.6	114.5	112.7	123.6
Other Current Liabilities	2,496	1,085	994.2	1,512	1,678
Total Current Liabilities	25,938	24,123	14,550	16,369	17,165
Long-Term Debt	1,219	-	-	-	-
Long-Term Leases	447.6	467.7	628.8	692.3	721.4
Pension & Post-Retirement Benefits	645.7	270.9	90.2	57.2	-
Other Long-Term Liabilities	2,685	972.2	1,005	1,005	958.1
Total Liabilities	30,936	25,834	16,274	18,124	18,845

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	393.1	393.1	393.1	393.1	393.1
Additional Paid-In Capital	7,484	7,484	7,484	7,484	7,484
Retained Earnings	48,543	43,945	40,273	35,687	43,991
Comprehensive Income & Other	327.9	87.8	32.4	140.8	507.2
Total Common Equity	56,748	51,909	48,182	43,705	52,376
Minority Interest	-58.3	-14.2	-	-	-
Shareholders' Equity	56,690	51,895	48,182	43,705	52,376
Total Liabilities & Equity	87,626	77,729	64,456	61,828	71,220

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	14,299	12,575	5,132	7,220	7,171
Net Cash (Debt)	-12,336	-11,740	-3,930	-6,465	-6,560
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-62.76	-59.73	-19.99	-32.89	-33.37
Filing Date Shares Outstanding	196.56	196.56	196.56	196.56	196.56
Total Common Shares Outstanding	196.56	196.56	196.56	196.56	196.56
Working Capital	19,788	16,755	16,236	12,731	11,443
Book Value Per Share	288.70	264.09	245.12	222.34	266.46
Tangible Book Value	53,880	51,909	48,182	43,705	50,827
Tangible Book Value Per Share	274.11	264.09	245.12	222.34	258.58
Land	1,070	1,070	1,013	1,017	931.4
Buildings	8,250	7,810	7,465	7,068	5,277
Machinery	35,407	30,646	28,487	24,961	18,291
Construction In Progress	6,337	8,372	5,244	6,013	22,058
Leasehold Improvements	44.7	36	18.3	7.9	7.3

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 31, 2026

Data Sources Report a data error